05:57 EST Novo Nordisk (NVO): Cagrisema weight loss showed superiority over semaglutide
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
- Lennox to replace Catalent in S&P 500 at open on 12/23
- Novo Nordisk Completes Strategic Acquisition to Enhance Manufacturing Capacity
- Trump’s Key Advisors Are Split on Whether Medicare Should Cover Weight-Loss Drugs
- Viking Therapeutics lower after Merck signs pact with Hansoh for GLP-1 drug
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
